NCT05728944 - Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia | Biotech Hunter

Enrollment

229

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

December 14, 2023

Study Completion Date

January 24, 2024

Conditions

PresbyopiaNear VisionMiosisEye Diseases

Interventions

DRUG

Aceclidine+Brimonidine combination ophthalmic solution

Aceclidine + Brimonidine combination ophthalmic solution

DRUG

Aceclidine

Aceclidine ophthalmic solution

DRUG

Vehicle

Proprietary vehicle ophthalmic solution

Trial Locations (13)

34429

Site #205, Crystal River

36301

Site #209, Dothan

40206

Site #211, Louisville

43065

Site #207, Powell

58078

Site #212, West Fargo

59718

Site #215, Bozeman

63128

Site #208, St Louis

85260

Site #216, Scottsdale

92037

Site #214, La Jolla

92663

Site #203, Newport Beach

97401

Site #213, Eugene

06810

Site #204, Danbury

02888

Site #217, Warwick